AstraZeneca plc (LON:AZN) Earns Sell Rating from Goldman Sachs Group, Inc. (The)
Goldman Sachs Group, Inc. (The) reiterated their sell rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Friday morning. Goldman Sachs Group, Inc. (The) currently has a GBX 3,900 ($50.93) target price on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued research reports about the company. Liberum Capital reiterated a buy rating and set a GBX 5,100 ($66.60) target price on shares of AstraZeneca plc in a report on Tuesday, March 21st. Deutsche Bank AG restated a buy rating and set a GBX 5,500 ($71.82) price objective on shares of AstraZeneca plc in a research note on Tuesday, March 21st. Berenberg Bank increased their price objective on shares of AstraZeneca plc from GBX 5,450 ($71.17) to GBX 5,670 ($74.04) and gave the stock a buy rating in a research note on Monday, March 20th. Societe Generale restated a buy rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. Finally, Kepler Capital Markets restated a buy rating and set a GBX 5,000 ($65.29) price objective on shares of AstraZeneca plc in a research note on Friday, April 21st. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 5,251.80 ($68.58).
AstraZeneca plc (LON AZN) traded up 0.58% during mid-day trading on Friday, reaching GBX 5069.00. The company had a trading volume of 1,763,249 shares. The firm’s 50-day moving average price is GBX 5,259.89 and its 200-day moving average price is GBX 4,769.91. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The stock’s market cap is GBX 64.17 billion.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.